Partenaires

Présentation du CNRS Présentation de l′Université Faculté de Pharmacie


Rechercher

Sur ce site


Accueil > Teams > Design and Synthesis of bioactives Compounds - CoSMIT > The project "synthesis of anti-cancer molecules having diminished side effects" awarded to Dr. Olivier Provot at the 11th price of valorisation’s price of Paris-Sud University

The project "synthesis of anti-cancer molecules having diminished side effects" awarded to Dr. Olivier Provot at the 11th price of valorisation’s price of Paris-Sud University

The award ceremony for the valuation of the University Paris-Sud took place Thursday, November 20, 2014, at the Ecole Polytech Paris-Sud, on Orsay’s university campus.

The laboratory of medicinal chemistry at the Faculty of Pharmacy received the second prize which was gave by the rector of the catholic university of Louvain, Rik Torfs, and the deputy in charge of the competitiveness and Investment at the department of the National Research Agency, Jean-Michel Leroux.

The winning project presented by Dr. Provot concerns the discovery of small molecules related to a natural molecule, combretastatin A-4, which can be used in the treatment of thyroid cancer and ovarian cancer with efficacy and which are devoid of side-effects. Preliminary results showed that new original molecules were more stable [1], [2] and more efficient than the natural CA-4 against a variety of human cancer cells. [3] Toxicity studies are currently under study.


[1(a) Patent, FR 0754280, PCT N° EP2008/054118 (WO 2008122620). (b) J. Med. Chem. 2009, 52, 4538-4542. (c) ChemMedChem. 2009, 4, 1912-1924.

[2(a) Patent FR 08/53694; (WO 2009/147217 A1). (b) ChemMedChem. 2011, 6, 488-497.

[3Patent, FR 1453142, 09 April 2014.